Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
Conditions
Keywords
Epithelial Ovarian Cancer, FIGO (Int Federation of Gyn and Ob )Stage III or Stage IV, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma Failing
Brief summary
This study will test the hypothesis that adding pegylated IFN (IFN)a-2b to denileukin diftitox improves the potential of denileukin diftitox alone to deplete regulatory T cells (Tregs) and will thereby boost tumor immunity in patients with advanced-stage epithelial ovarian cancers, enhancing treatment efficacy.
Detailed description
The aims of this study are to: * Assess the efficacy of adding pegylated IFN-α2b to denileukin diftitox to treat selected advanced-stage epithelial ovarian cancers * Test the immune-modulating effects of adding pegylated IFN-α2b to denileukin diftitox in ovarian cancer patients and relate them to clinical efficacy * Identify any toxicity associated with pegylated IFN-α2b plus denileukin diftitox treatment in these patients * Identify practical means to dose the immunomodulating agents denileukin diftitox and pegylated IFN-α2b based on immunopharmacodynamic metrics
Interventions
DRUGDenileukin Diftitox/SC Pegylated IFNα-2a
Sponsors
The University of Texas Health Science Center at San Antonio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Able to provide informed consent * Not on immune-modulating drugs, except those used as denileukin diftitox premedication, unless the principal investigator grants an exception (which exception must be documented in writing) * Histologically proven epithelial (non-germ cell, non-stromal cell) cancer of the ovaries, fallopian tubes or extraovarian peritoneal carcinoma. Clinical recurrence without documented pathology is acceptable * FIGO stage III or IV with failed prior first-line therapy, or ineligible for or intolerant of such therapy * Measurable disease as defined in section 6 within 30 days of study enrollment * Blood hemoglobin ≥ 8.5 gm/dl within 7 days of study enrollment * Absolute neutrophil count ≥ 750/mm3 within 7 days of study enrollment * Platelet count ≥ 40,000/mm3 within 7 days of study enrollment * SGOT (serum glutamic oxaloacetic transaminase) ≤10 x upper limit of normal within 7 days of study enrollment * Normal TSH (thyroid-stimulating hormone ) within 30 days of study enrollment * No chemotherapy in the 14 days prior or radiation therapy in the thirty days prior to initiation of treatment on this study * No other concurrent chemotherapy, surgery or radiation therapy during this protocol except surgery or radiation therapy to control symptoms with concurrence of the principal investigator * No contraindication to any study treatment * No active major medical problems, including untreated or uncontrolled infections * Beck Depression Index ≥15 within 30 days of study enrollment * If of reproductive potential, a negative urine pregnancy test within 3 days of study enrollment, and agreement to use adequate contraception. Pregnancy testing will continue monthly while on treatment unless the subject is no longer able to become pregnant or there is sufficient justification otherwise * Not breast feeding * Life expectancy ≥ six months * ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2 * Serum albumin ≥ 1.8 gm/dl * Age ≥ 18 years * Acceptable baseline retinal examination within 30 days of study enrollment * No active substance abuse in the prior 6 months * Patients failing single agent denileukin diftitox in the ongoing trial A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line Therapy are eligible for this trial provided that three or more weeks have elapsed since their last denileukin diftitox infusion and they meet all eligibility criteria and successfully undergo all screening examinations for this trial.
Exclusion criteria
* Unable to tolerate phlebotomy * Germ cell or stromal cell cancers of the ovaries, or other currently uncured cancer * Active autoimmune disease including systemic lupus erythematosus, psoriasis, or inflammatory bowel disease that is not medically controlled * Autoimmune hepatitis, whether medically controlled or not * Contraindication to any study drug * Known hypersensitivity to denileukin diftitox, pegylated IFN-α2a or any of their components or excipients * Current pregnancy or breast feeding * Inability to document adequate contraception if a female of reproductive potential * On other immune-modulating drugs, except denileukin diftitox premedications or those approved by the principal investigator * Chemotherapy within 14 days or radiation therapy within the thirty days prior to initiation of study treatment * Life expectancy less than six months * Serum albumin \< 1.8 gm/dl * Blood hemoglobin \< 8.5 gm/dl * ECOG performance status\> 2 * Symptomatic coronary artery disease (including uncontrolled angina, congestive heart failure, and the like) * Uncontrolled hypertension (diastolic BP consistently \>100 mm Hg or systolic BP consistently \>160 mm Hg on a regular basis) * Uncontrolled, symptomatic cardiac arrhythmia * Retinopathy associated with significant visual impairment * Beck Depression Index \>15 * Active substance abuse in the prior 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Response Rate | every 3 months until the date of first documented progression or date of death from any cause, assessed up to 2 years when study terminated early | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Response = CR + PR. Failure to respond criteria are not based on RECIST criteria, which have unclear application to immune-based clinical trials. Instead, novel lack-of-failure criteria, rather than failure-of-success criteria have been written to avoid stopping therapy prematurely without compromising patient safety, to accommodate the uncertainties of assessing failure in this setting. The criteria as written are based on sound medical, scientific and ethical principles. The trial is further designed to help establish the utility of these novel criteria. |
Countries
United States
Participant flow
Recruitment details
This study was open to accrual on 7/29/2009 and closed to accrual on 6/27/2011. Subjects were seen at The Cancer Therapy and Research Center @ The University of Texas Health Science Center San Antonio.
Pre-assignment details
* Intercurrent illness that prevents further administration of treatment * Unacceptable adverse event(s) * Patient withdraws from study * General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.
Participants by arm
| Arm | Count |
|---|---|
| Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a : | 2 |
| Total | 2 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | lack of funding | 2 |
Baseline characteristics
| Characteristic | Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Age, Continuous | 57 years STANDARD_DEVIATION 3 |
| Region of Enrollment United States | 2 participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 2 |
| serious Total, serious adverse events | 0 / 2 |
Outcome results
Primary
Clinical Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Response = CR + PR. Failure to respond criteria are not based on RECIST criteria, which have unclear application to immune-based clinical trials. Instead, novel lack-of-failure criteria, rather than failure-of-success criteria have been written to avoid stopping therapy prematurely without compromising patient safety, to accommodate the uncertainties of assessing failure in this setting. The criteria as written are based on sound medical, scientific and ethical principles. The trial is further designed to help establish the utility of these novel criteria.
Time frame: every 3 months until the date of first documented progression or date of death from any cause, assessed up to 2 years when study terminated early
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A | Clinical Response Rate | 2 participants |